The cardiovascular promise of GLP-1 receptor agonists like semaglutide may be undermined by an overlooked consequence: substantial muscle loss alongside fat reduction. This metabolic trade-off challenges the assumption that dramatic weight loss automatically translates to optimal heart health outcomes. The European Heart Journal analysis reveals that current anti-obesity medications trigger muscle catabolism through multiple pathways beyond simple caloric restriction. The drugs induce anabolic resistance—where muscle tissue becomes less responsive to protein synthesis signals—while simultaneously disrupting hormonal cascades that normally preserve lean mass during weight loss. This muscle degradation occurs even when patients follow recommended protein intake guidelines. The implications extend far beyond aesthetics. Skeletal muscle serves as a metabolic reservoir, glucose disposal site, and inflammatory regulator. Its loss during pharmaceutical weight reduction may compromise long-term metabolic resilience and potentially limit sustained cardiovascular protection. The analysis identifies promising countermeasures emerging from clinical pipelines. Myostatin inhibitors and selective androgen receptor modulators show potential for preserving muscle quality during GLP-1 therapy. However, resistance training remains the most validated intervention for maintaining functional capacity during pharmacologic weight loss. The research advocates for a fundamental recalibration of obesity treatment success metrics. Rather than celebrating total pounds lost, clinicians should prioritize body composition optimization—maximizing fat loss while preserving or enhancing muscle mass. This approach may prove more predictive of durable cardiovascular risk reduction than traditional weight-centric endpoints. Current trial designs inadequately capture these nuanced body composition changes, potentially overestimating long-term therapeutic benefits.